AnaptysBio (ANAB) Aktienübersicht
AnaptysBio, Inc. ist ein Biotechnologieunternehmen in der klinischen Phase, das sich auf die Bereitstellung von immunologischen Therapeutika für Autoimmun- und Entzündungskrankheiten in den Vereinigten Staaten konzentriert. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 4/6 |
| Künftiges Wachstum | 5/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 5/6 |
| Dividenden | 2/6 |
ANAB Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Top Community Narratives
AnaptysBio, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$63.42 |
| 52-Wochen-Hoch | US$73.30 |
| 52-Wochen-Tief | US$17.11 |
| Beta | 0.38 |
| 1 Monat Veränderung | 25.91% |
| 3 Monate Veränderung | 1.59% |
| 1 Jahr Veränderung | 167.03% |
| 3 Jahre Veränderung | 213.80% |
| 5 Jahre Veränderung | 144.02% |
| Veränderung seit IPO | 273.06% |
Aktuelle Nachrichten und Updates
ANAB has a scaling and rising royalty stream, one up and coming new royalty, a loan that dies in 2027 which will result in a doubling
TLDR : ANAB has a scaling and rising royalty stream, one up and coming new royalty, a loan that dies in 2027 which will result in a doubling of revenue, and a lawsuit that could soon double the value of the stock. Sign up for my Substack for more special situations.AnaptysBio (ANAB) Stock Could Be 84% Below Fair Value After Choppy Trading
AnaptysBio (ANAB) has drawn renewed attention after recent trading left the stock at a last close of $57.61. The company’s clinical-stage immunology portfolio and collaborations are in focus for investors. See our latest analysis for AnaptysBio. Recent trading has been choppy for AnaptysBio, with the share price slipping 3.19% over the last day and also down over the past month and quarter, yet supported by a 28.16% year to date share price return and a very large 1 year total shareholder...Recent updates
ANAB has a scaling and rising royalty stream, one up and coming new royalty, a loan that dies in 2027 which will result in a doubling
TLDR : ANAB has a scaling and rising royalty stream, one up and coming new royalty, a loan that dies in 2027 which will result in a doubling of revenue, and a lawsuit that could soon double the value of the stock. Sign up for my Substack for more special situations.AnaptysBio (ANAB) Stock Could Be 84% Below Fair Value After Choppy Trading
AnaptysBio (ANAB) has drawn renewed attention after recent trading left the stock at a last close of $57.61. The company’s clinical-stage immunology portfolio and collaborations are in focus for investors. See our latest analysis for AnaptysBio. Recent trading has been choppy for AnaptysBio, with the share price slipping 3.19% over the last day and also down over the past month and quarter, yet supported by a 28.16% year to date share price return and a very large 1 year total shareholder...AnaptysBio: 'Hold' As Spin-Off Shifts Pipeline To First Tracks Biotherapeutics
Summary AnaptysBio has spun off its biopharma pipeline into First Tracks Biotherapeutics, shifting to a royalty-focused, virtual business model. I maintain a "Hold" rating on both ANAB and TRAX, given the need for further clinical data and clarity on pipeline advancement and partnerships. ANAB retains royalty streams from JEMPERLI [GlaxoSmithKline] and imsidolimab (Vanda Pharmaceuticals), with JEMPERLI sales growing and a PDUFA date for imsidolimab set for Dec 2026. TRAX's value hinges on upcoming ANB033 data in celiac disease [Q4 2026] and EoE [mid-2027], and potential strategic financing for rosnilimab in RA Q2 2026. Read the full article on Seeking AlphaAnaptysBio, Inc.'s (NASDAQ:ANAB) Share Price Not Quite Adding Up
With a median price-to-sales (or "P/S") ratio of close to 8.6x in the Biotechs industry in the United States, you could...Shareholders May Be More Conservative With AnaptysBio, Inc.'s (NASDAQ:ANAB) CEO Compensation For Now
Key Insights AnaptysBio to hold its Annual General Meeting on 17th of June Salary of US$685.4k is part of CEO Dan...Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates
It's been a mediocre week for AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders, with the stock dropping 11% to US$19.68 in...Is AnaptysBio (NASDAQ:ANAB) Using Debt Sensibly?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...AnaptysBio, Inc.'s (NASDAQ:ANAB) Price Is Right But Growth Is Lacking After Shares Rocket 30%
Despite an already strong run, AnaptysBio, Inc. ( NASDAQ:ANAB ) shares have been powering on, with a gain of 30% in the...AnaptysBio: A Shadow Of Its Former Self
Summary ANAB remains risky despite new clinical data and partnerships; past successes haven't been replicated, and management's transparency issues raise concerns. The recent deal for Imsidolimab reflects low confidence in the drug's market potential, despite positive phase 3 results. Rosnilimab showed promising trial results but failed to differentiate significantly from existing treatments, raising doubts about its competitive edge. Financials show a cash runway of 6-7 quarters, but high expenses and limited revenue sources maintain the risk profile. Read the full article on Seeking AlphaAnaptysBio, Inc. (NASDAQ:ANAB) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected
AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders would be excited to see that the share price has had a great month...AnaptysBio: Doubts About Cash And Upcoming Rheumatoid Arthritis Readout
Summary The failure of ANB032 in Phase 2B for atopic dermatitis has shifted focus to rosnilimab, which faces significant competition and uncertain prospects. Rosnilimab's upcoming Phase 2B results for rheumatoid arthritis in February 2025 are crucial, but Eli Lilly's discontinuation of a similar drug raises concerns. If rosnilimab fails to deliver, the company's mid-stage pipeline may not hold much promise any more. Anaptys estimates that it will have about $415 million in the bank at the end of the year. Read the full article on Seeking AlphaAnaptysBio: An Immunology Pipeline-In-A-Pill Company Worth Watching
Summary AnaptysBio has been able to use its technology to develop 2 compelling lead drug candidates. Their pipeline has 2 key readouts in December 2024 and February 2025 worth monitoring. The near-term catalysts include a Phase 2b trial for the drug candidates rosnilimab and ANB032, which are crucial for re-evaluating AnaptysBio’s stock value. Despite this promising pipeline and experienced leadership team, the competitive landscape within immunology and potential clinical trial failures present substantial risks to AnaptysBio’s progress. Read the full article on Seeking AlphaAnaptysBio, Inc. (NASDAQ:ANAB) May Have Run Too Fast Too Soon With Recent 33% Price Plummet
The AnaptysBio, Inc. ( NASDAQ:ANAB ) share price has fared very poorly over the last month, falling by a substantial...AnaptysBio: Too Risky, Especially After GSK Drops Its Related Programs
Summary ANAB has a past history of successes. There are two molecules in phase 2, but with no patient data. The GSK news has hurt the stock. Read the full article on Seeking AlphaAnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point
Summary AnaptysBio, Inc. 14-week results from the phase 2b study, using ANB032 for the treatment of patients with moderate-to-severe Atopic Dermatitis, expected in December 2024. The global Atopic dermatitis market is expected to reach $19.49 billion by 2034. Top-line 12-week data from the phase 2b study, using rosnilimab for the treatment of patients with moderate-to-severe rheumatoid arthritis, expected in Q1 of 2025. The company raised $100 million in gross proceeds through a registered direct stock offering, substantially increasing its cash runway. Read the full article on Seeking AlphaAnaptysBio: Interesting Prospects, But Wait For The Dip (Rating Downgrade)
Summary AnaptysBio, Inc. receives a "Hold" rating for its U.S.-listed shares. It shows a 16.42% increase in stock market value since the last "Buy" rating. AnaptysBio's immunotherapy portfolio includes promising projects such as Rosnilimab, ANB032, ANB033, Imsidolimab, and Etokimab, with positive progress and the potential to develop into a profitable source of income. Financial partnership with GSK plc also bodes favorably with AnaptysBio's hopes for additional growth, despite a net loss in the first quarter of 2024. As in the past, the apparent continuation of Fed tightening for a longer period than market participants expect will create downward pressure. This analysis concludes that there are good reasons to believe that another sharp price drop is on the horizon. Read the full article on Seeking AlphaNews Flash: Analysts Just Made A Captivating Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts
AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders will have a reason to smile today, with the analysts making substantial...Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates
There's been a notable change in appetite for AnaptysBio, Inc. ( NASDAQ:ANAB ) shares in the week since its...Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Aktionärsrenditen
| ANAB | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 0.4% | 4.1% | 1.6% |
| 1Y | 167.0% | 41.1% | 18.6% |
Rendite im Vergleich zur Industrie: ANAB übertraf die Branche US Biotechs , die im vergangenen Jahr eine Rendite von 41.1 erzielte.
Rendite vs. Markt: ANAB übertraf den Markt US, der im vergangenen Jahr eine Rendite von 18.6 erzielte.
Preisvolatilität
| ANAB volatility | |
|---|---|
| ANAB Average Weekly Movement | 11.5% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiler Aktienkurs: Der Aktienkurs von ANAB war in den letzten 3 Monaten im Vergleich zum US -Markt volatil.
Volatilität im Zeitverlauf: ANABDie wöchentliche Volatilität (11%) war im vergangenen Jahr stabil, liegt aber immer noch höher als bei 75 % der US Aktien.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2005 | 104 | Dan Faga | www.anaptysbio.com |
AnaptysBio, Inc. ist ein Biotechnologieunternehmen im klinischen Stadium, das sich auf die Bereitstellung von immunologischen Therapeutika für Autoimmun- und Entzündungskrankheiten in den Vereinigten Staaten konzentriert. Zu den Produkten des Unternehmens gehören Rosnilimab, ein selektiver pathogener T-Zell-Deplete, der eine Phase-2b-Studie zur Behandlung von mittelschwerer bis schwerer rheumatoider Arthritis abgeschlossen hat; ANB033, ein CD122-Antagonist, der sich in einer Phase-1b-Studie zur Behandlung von Zöliakie und eosinophiler Ösophagitis befindet; ANB101, ein BDCA2-Modulator-Antikörper, der sich in einer Phase-1a-Studie befindet und spezifisch auf plasmazytoide dendritische Zellen abzielt, die Interferon-Sekretion hemmt und die Antigenpräsentation moduliert; Dostarlimab, ein PD-1-Antagonist für verschiedene solide Tumorindikationen; und Imsidolimab, ein Antikörper, der den Interleukin-36-Rezeptor hemmt und sich in der Phase-3-Entwicklung für die Behandlung der generalisierten pustulösen Psoriasis befindet. Das Unternehmen konzentriert sich auf die Entwicklung verschiedener Antikörperprogramme, die im Rahmen von Kooperationen zu präklinischen und klinischen Meilensteinen fortgeschritten sind.
AnaptysBio, Inc.'s Grundlagenzusammenfassung
| ANAB grundlegende Statistiken | |
|---|---|
| Marktanteil | US$1.85b |
| Gewinn(TTM) | -US$26.79m |
| Umsatz(TTM) | US$232.39m |
Ist ANAB zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| ANAB Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$232.39m |
| Kosten der Einnahmen | US$128.78m |
| Bruttogewinn | US$103.61m |
| Sonstige Ausgaben | US$130.39m |
| Gewinn | -US$26.79m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -0.92 |
| Bruttomarge | 44.58% |
| Nettogewinnspanne | -11.53% |
| Schulden/Eigenkapital-Verhältnis | 2,069.1% |
Wie hat sich ANAB auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/05 21:18 |
| Aktienkurs zum Tagesende | 2026/07/02 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
AnaptysBio, Inc. wird von 19 Analysten beobachtet. 7 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Neena Bitritto-Garg | Baird |
| Etzer Darout | Barclays |
| Michael King | Citizens JMP Securities, LLC |